SALT LAKE CITY, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted patients' risk of death from early-stage lung adenocarcinoma within five years of being diagnosed. A key finding of the validation study is that patients with a high-risk myPlan prognostic score had approximately twice the number of lung cancer related deaths compared to patients with a low-risk score. Myriad is presenting these results and another myPlan clinical study this week at the International Association for the Study of Lung Cancer (IASLC) 15 th World Conference on Lung Cancer in Sydney, Australia. myPlan Lung Cancer is the only prognostic test on the market today that can assess a patient's risk of lung cancer mortality and thereby guide the physician in determining which patients may benefit from post-surgical chemotherapy. "The Myriad myPlan Lung Cancer test provides new information that can identify people at high risk of lung cancer recurrence and will enable us to offer these patients additional therapy to improve their survival," said Raphael Bueno, M.D., Associate Chief of Thoracic Surgery at Brigham and Women's Hospital and Harvard Medical School. "Once we know a patient's risk profile, we can align our clinical management strategies to achieve better medical outcomes and save more lives." The two studies being presented at the IASLC annual meeting are: Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma. [Bueno et al., Poster: Oct. 28, 2013, 3:30 p.m. – 4:15 p.m. AEDT] This study evaluated the association of cell cycle progression (CCP) genes with five-year lung cancer mortality in 650 patients diagnosed with stage 1 or 2 lung adenocarcinoma. In this clinical validation study, patients with a high-risk Myriad myPlan Lung Cancer prognostic score had a significantly higher average five-year mortality rate (35 percent) than patients with a low-risk score (18 percent). The prognostic score (CCP + tumor stage) segregated stage 1A to 2B patients with five-year risk estimates ranging from 11 percent to 68 percent. This study demonstrated that the myPlan Lung Cancer prognostic score was statistically significant in predicting five-year lung cancer mortality, and was significantly more predictive than tumor staging information alone. These data strongly support the use of the Myriad myPlan Lung Cancer test to help stratify patients' risk profiles and determine which patients are candidates for conservative management with surgery alone versus more intensive therapy based on a higher personal risk profile.